Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis;Guía de uso adecuado de modelos animals para el desarrollo de terapias en esclerosis múltiple

Revista de Neurologia

Volumn 54, Issue 2, 2012, Pages 114-124

  Moreno, Beatriz ^a,b   Espejo, Carmen ^a   Mestre, Leyre ^a,c,d   Suardiaz, Margarita ^a,e   Clemente, Diego ^a,f   de Castro, Fernando ^a,f   Fernández Fernández, Óscar ^a,e   Montalban, Xavier ^c   Villoslada, Pablo ^a,b   Guaza, Carmen ^a,d  

^a Red Española de Esclerosis Múltiple   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO CAJAL   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

Animal models; Experimental design; Multiple sclerosis; Preclinical research; Quality criteria

Indexed keywords

ANIMAL MODEL; ARTICLE; EXPERIMENTAL MODEL; METHODOLOGY; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE;

EID: 84856604868     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5402.2011424     Document Type: Article

References (47)

1. Baxter AG. Te origin and application of experimental auto -immune encephalomyelitis. Nat Rev Immunol 2007; 7: 904-12.
2. Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol 2009; 39: 2031-5.
3. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6: 88-91.
4. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fne specifcity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995; 25: 1951-9.
5. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice defcient in either the chemokine macrophage infammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30: 1410-5.
6. Zamvil SS, Steinman L. Te T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 1990; 8: 579-621.
7. Weller RO. Animal models in demyelinating disease. Curr Opin Neurol Neurosurg 1991; 4: 221-30.
8. Stepaniak JA, Wolf NA, Sun D, Swanborg RH. Interstrain variability of autoimmune encephalomyelitis in rats: multiple encephalitogenic myelin basic protein epitopes for DA rats. J Neuroimmunol 1997; 78: 79-85.
9. Lenz DC, Wolf NA, Swanborg RH. Strain variation in autoimmunity: attempted tolerization of DA rats results in the induction of experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 1763-8.
10. Polman CH, Matthaei I, De Groot CJ, Koetsier JC, Sminia T, Dijkstra CD. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 1988; 17: 209-16.
11. Weissert R, Wallström E, Storch MK, Steferl A, Lorentzen J, Lassmann H, et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998; 102: 1265-73.
12. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specifc immune intervention. Cell 1988; 54: 263-73.
13. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989; 59: 247-55.
14. Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, Anderson S, Hemmer B, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74: 1127-35.
15. Miller SD, Karpus WJ. Te immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol Today 1994; 15: 356-61.
16. Lipton HL. Teiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun 1975; 11: 1147-55.
17. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Teiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev 2004; 17: 174-207.
18. Kappel CA, Melvold RW, Kim BS. Infuence of sex on susceptibility in the Teiler's murine encephalomyelitis virus model for multiple sclerosis. J Neuroimmunol 1990; 29: 15-9.
19. Croxford JL, Olson JK, Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Teiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev 2002; 1: 251-60.
20. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
21. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11: 335-9.
22. Tsunoda I, Fujinami RS. Inside-out versus outside-in models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol 2002; 24: 105-25.
23. Drescher KM, Rivera-Quiñones C, Lucchinetti CF, Rodríguez M. Failure of treatment with linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. J Neuroimmunol 1998; 88: 111-9.
24. Black JA, Waxman SG, Smith KJ. Remyelination of dorsal column axons by endogenous Schwann cells restores the normal pattern of Nav1.6 and Kv1.2 at nodes of Ranvier. Brain 2006; 129: 1319-29.
25. Matsushima GK, Morell P. Te neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11: 107-16.
26. Papenfuss TL, Rogers CJ, Gienapp I, Yurrita M, McClain M, Damico N, et al. Sex diferences in experimental autoimmune encephalomyelitis in multiple murine strains. J Neuroimmunol 2004; 150: 59-69.
27. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. Te increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19: 466-71.
28. Teuscher C, Bunn JY, Fillmore PD, Butterfeld RJ, Zachary JF, Blankenhorn E P. Gender, age, and season at immunization uniquely infuence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am J Pathol 2004; 165: 1593-602.
29. Ligouri M, Marrosu MG, Pugliatti M, Giuliani F, De Robertis F, Cocco E, et al. Neurological sciences age at onset in multiple sclerosis. Neurol Sci 2000; 21 (Suppl 2): S825-9.
30. DeLuca LE, Pikor NB, O'Leary J, Galicia-Rosas G, Ward LA, Defreitas D, et al. Substrain diferences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis. J Immunol 2010; 184: 3174-85.
31. Bebarta V, Luyten D, Heard K. Emergency medicine animal research: does use of randomization and blinding afect the results? Acad Emerg Med 2003; 10: 684-7.
32. Miller SD, Karpus WJ, Davidson TS. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol 2010; chapter 15: unit 15.1.
33. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J. TNF is a potent anti-infammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
34. Dal Canto RA, Shaw MK, Nolan GP, Steinman L, Fathman CG. Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin Immunol 1999; 90: 10-4.
35. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, Von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4.
36. Wiendl H, Hohlfeld R. Terapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16: 183-200.
37. Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid FN, Boyton RJ, et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 2005; 174: 1938-46.
38. U.S. Department of Health and Human Services. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Pharmacology and toxicology. Rockville, MD: CDER/FDA; 2005.
39. Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J Autoimmun 1992; 5: 675-90.
40. Schifenbauer J, Johnson HM, Butfloski EJ, Wegrzyn L, Soos JM. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 1993; 90: 8543-6.
41. Fleming KK, Bovaird JA, Mosier MC, Emerson MR, LeVine SM, Marquis JG. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 170: 71-84.
42. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-8.
43. Körner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune infammation defned by gene targeting. J Exp Med 1997; 186: 1585-90.
44. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998; 95: 675-80.
45. Gold BG, Voda J, Yu X, McKeon G, Bourdette DN. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J Neurosci Res 2004; 77: 367-77.
46. Buddeberg BS, Kerschensteiner M, Merkler D, Stadelmann C, Schwab ME. Behavioral testing strategies in a localized animal model of multiple sclerosis. J Neuroimmunol 2004; 153: 158-70.
47. De Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, Cabranes A, Pryce G, Baker D, et al. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of diferent motor-related disorders. Eur Neuropsychopharmacol 2006; 16: 7-18.